País: Estats Units
Idioma: anglès
Font: NLM (National Library of Medicine)
PARICALCITOL (UNII: 6702D36OG5) (PARICALCITOL - UNII:6702D36OG5)
AbbVie Inc.
PARICALCITOL
PARICALCITOL 2 ug in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
ZEMPLAR is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. ZEMPLAR is contraindicated in patients with: - Hypercalcemia [see Warnings and Precautions ( 5.1 )] - Vitamin D toxicity [see Warnings and Precautions ( 5.1 )] - Known hypersensitivity to paricalcitol or any of the inactive ingredients in ZEMPLAR. Hypersensitivity adverse reactions have been reported [e.g., angioedema (including laryngeal edema) and urticaria] [see Adverse Reactions ( 6.2 )] . Risk Summary Limited data with ZEMPLAR in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. There are risks to the mother and fetus associated with chronic kidney disease in pregnancy (see Clinical Considerations ) . In animal reproduction studies, slightly increased embryofetal loss was observed in pregnant rats and rabbits administered paricalcitol intravenously during the period of organogenes
ZEMPLAR injection is a clear, colorless solution available in cartons of 25 vials as follows: Store at 25°C (77°F). Excursions permitted between 15° to 30°C (59° to 86°F). Discard any unused portion of the single-dose vial after use. The contents of the multiple-dose vial remain stable up to seven days after initial use when stored at controlled room temperature.
New Drug Application
ZEMPLAR- PARICALCITOL INJECTION, SOLUTION ABBVIE INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ZEMPLAR SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ZEMPLAR. ZEMPLAR (PARICALCITOL) INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1998 INDICATIONS AND USAGE ZEMPLAR is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease on dialysis (1). DOSAGE AND ADMINISTRATION Ensure serum calcium is not above the upper limit of normal before initiating (2.1) Administer ZEMPLAR intravenously through a hemodialysis vascular access at any time during dialysis (2.1). Adult Dose: Initiate at 0.04 mcg/kg to 0.1 mcg/kg (2.8 mcg to 7 mcg) no more frequently than every other day (2.2). Target maintenance dose to intact parathyroid hormone (PTH) levels within the desired therapeutic range and serum calcium within normal limits (2.2). Monitor serum calcium frequently (e.g., twice weekly) and intact PTH levels every 2 to 4 weeks after dose initiation or adjustment (2.2). See Table 1 in the full prescribing information for titration recommendations based upon intact PTH levels (2.2). Suspend or decrease the dose for persistent abnormally low intact PTH or serum calcium consistently above the normal range (2.2). Pediatric Dose: Initiate ZEMPLAR as an intravenous bolus dose of: ○ 0.04 mcg/kg if baseline intact PTH is less than 500 pg/mL, or ○ 0.08 mcg/kg if baseline intact PTH is 500 pg/mL or greater (2.3) Target maintenance dose to intact PTH levels within the desired therapeutic range and serum calcium within normal limits (2.3). Monitor serum calcium frequently (e.g., twice weekly) and intact PTH levels every 2 to 4 weeks after dose initiation or adjustment (2.3). See Table 2 in the full prescribing information for titration recommendations based upon intact PTH levels (2.3). Suspend or decrease the dose for persistent abnormally low inta Llegiu el document complet